Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

bmitted marketing applications for fidaxomicin in the EU and the U.S., and presented additional data showing that CDI patients treated with fidaxomicin experienced 47% fewer recurrences than patients treated with vancomycin," said Pedro Lichtinger, Optimer's President and CEO.  "With the progress we made in 2010, we believe fidaxomicin, if approved, is positioned to become a first line treatment for CDI for patients at risk of recurrence.  We expect 2011 to be a year of commercial execution marked by the potential launch of fidaxomicin."

"The rapid progress we've made so far in 2011 is a testament to the strength of the fidaxomicin program," added Lichtinger.  "In 2011 we have signed a partnership agreement with Astellas to commercialize fidaxomicin in Europe and certain other countries in the Middle East, Africa and CIS, added key commercialization capabilities to our management team and published Phase 3 data in The New England Journal of Medicine."

The Company expects to provide 2011 financial guidance after obtaining further clarity on the outcome of the Advisory Committee Meeting and achieving an FDA registration.

Optimer 2010 and Recent Highlights

  • Announced collaboration with Astellas Pharma Europe Ltd. to develop and commercialize fidaxomicin for the treatment of Clostridium difficile infection (CDI), in Europe and certain other countries in the Middle East, Africa, and the Commonwealth of Independent States.  Optimer received a $69.2 million upfront cash payment and is eligible to receive milestone payments of up to approximately 115.0 million Euros and tiered double-digit royalty payments on net sales of fidaxomicin in the territory.
  • Raised $73.1 million in net proceeds in a public offering of common stock in February 2011.  Also raised $51.2 million in net proceeds in a public offering of common stock in March 2010.
  • Fidaxomicin North American Phase 3 trial results w
    '/>"/>

  • SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... WASHINGTON , July 31, 2014  Today,s ... relievers serves as an important reminder for consumers ... reinforces the importance of initiatives such as the ... Dose consumer education campaign. Formed in ... health, healthcare provider and consumer organizations dedicated to ...
    (Date:7/31/2014)... 2014 De Pfizer Clinical Research Unit (PCRU) ... vrijwilligers van Japanse komaf voor medewerking aan klinisch onderzoek. ... is één van twee onderzoekseenheden van Pfizer , ... verbeteren door de ontdekking en ontwikkeling van nieuwe medicijnen. ... naar mannen en vrouwen van Japanse komaf – leeftijd ...
    (Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
    Breaking Medicine Technology:U.S. Health Coalition Calls for Continued Education on Acetaminophen, America's Most Common Drug Ingredient 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2
    ... and Chromium Histidinate Down-regulate Gene in Brain that ... and Efficacy of Nutrition 21,s Chromax Chromium PicolinatePURCHASE, ... NXXI ), the developer and marketer ... Diabetes Essentials brands, recently presented results of a ...
    ... First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is ... (Nasdaq: VVUS ), a biopharmaceutical company developing ... diabetes and sexual health, today announced that it has ... investigational drug, avanafil, in males with erectile dysfunction (ED). ...
    Cached Medicine Technology:New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 2New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 3New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 4VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3
    (Date:7/31/2014)... India (PRWEB) July 31, 2014 Reputation ... launched a new service named ‘Remove Bad Reviews’. The ... bad reviews are published on various review sites. ... the world of internet marketing, the sites that allow ... competitors in order to tailor the service. , ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 FITNESS SF, ... Francisco, announced that they will upgrade all locations to ... MyClub, and MoSo Pay. Motionsoft is a leading provider ... that automate member management and payments services for health ... relationship management suite, which FITNESS SF bundled with the ...
    (Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
    (Date:7/31/2014)... time after surgery may be reduced for patients taking ... new study. The study,s Irish researchers suspect that ... the amount of time surgical patients, wounds need to ... people who tend to have healing complications. "Statins ... in the world. While they are typically used to ...
    (Date:7/31/2014)... Ethane Web Technologies, an ISO ... new service named ‘Java Development’. The service cost ... designed the service after doing a serious study ... service being provided by other web development companies. ... promise outstanding Java Development service. ...
    Breaking Medicine News(10 mins):Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
    ... Julian ... searchbodydetox.com, a new informational Web site devoted to all aspects of whole body cleansing and ... Potomac, MD (Vocus) ... movement, is now a featured expert on searchbodydetox.com , a new informational Web site ...
    ... at Georgia State University have found that diets high in ... foods and beverages impaired the spatial memory of adult ... of Marise Parent, associate professor at Georgia State,s Neuroscience Institute ... a diet where fructose represented 60 percent of calories ingested ...
    ... , , MILWAUKEE, July 16 ... the nation in two different specialties, according to US News and ... same publication, St. Luke,s and Aurora Sinai Medical Center were recognized by ... , , (Logo: ...
    ... SWITZERLAND, July 16 /PRNewswire-FirstCall/ - BELLUS Health (International) Limited, ... Health, TSX: BLU), today announced that the Italian Ministry ... for VIVIMIND(TM) (homotaurine) as a food supplement. A certificate ... of the product in that country. This certificate opens ...
    ... , PHILADELPHIA, July 16 On Wednesday, ... its second quarter financial results for the three months ended June ... released to the London Stock Exchange at approximately 7:00 AM ... the announcement, Andrew Witty, Chief Executive Officer, Julian Heslop, Chief Financial ...
    ... ... just launched on Monday. , ... (Vocus) July 16, 2009 -- The National Practice Transition Network (NPTN), created ... practice sales and appraisals, is the first membership-based, commission-free organization to offer such a menu ...
    Cached Medicine News:Health News:Dr. Julian Whitaker Featured on Searchbodydetox.com 2Health News:Researchers find that eating high levels of fructose impairs memory in rats 2Health News:Aurora's Milwaukee Hospitals Recognized in US News and World Report 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 3Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2
    A One Piece Support Garment - any length or size...
    Body Suit w/Bra torso, Front Closure...
    Gynecomastia Vest...
    Ideal for breast compression and contouring breast cups....
    Medicine Products: